These results revealed that EGFR interacts with SHP-1 and inhibits activation of the Ras/Erk/GSK3β pathway, thus decreasing breast cancer cell proliferation and invasion, and consequently inhibiting breast cancer progression. This evidence concerns the gene PTPN6 and breast carcinoma.